Research programme: leucine-rich repeat kinase inhibitors - Lundbeck

Drug Profile

Research programme: leucine-rich repeat kinase inhibitors - Lundbeck

Alternative Names: LRRK2 inhibitors - Lundbeck

Latest Information Update: 02 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Vernalis; Zenobia Therapeutics
  • Class
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 30 Sep 2013 Lundbeck enters into a preclinical development agreement with Proximagen
  • 02 Jan 2013 Early research is ongoing
  • 16 Dec 2010 Lundbeck enters into a research collaboration with Vernalis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top